Medtronic plc - MDT STOCK NEWS

Medtronic announced the publication of results from the IN.PACT AV Access trial in The New England Journal of Medicine, highlighting the efficacy of the IN.PACT™ AV drug-coated balloon (DCB) for patients with end-stage renal disease (ESRD). The trial involved 330 subjects across three countries and demonstrated a significant reduction in the need for reinterventions—56% fewer than standard treatments—while maintaining a higher primary patency rate (82.2% vs. 59.5%). The study emphasizes the potential for improved patient quality of life and reduced healthcare costs.

Medtronic plc (NYSE: MDT) is set to announce its financial results for the first quarter of fiscal year 2021 on August 25, 2020. The results will be communicated through a news release at approximately 5:45 a.m. CDT, covering the period ending July 31, 2020. A webcast will follow at 7:00 a.m. CDT to discuss these results, accessible at http://investorrelations.medtronic.com/. Additionally, Medtronic plans to report subsequent quarterly results on November 24, 2020, February 23, 2021, and May 27, 2021.

Medtronic announced the first implant of its FDA-approved InterStim Micro neurostimulator for sacral neuromodulation (SNM) therapy at Cleveland Clinic. This device, the smallest rechargeable SNM system, enhances bladder and bowel control for over 55 million Americans suffering from overactive bladder (OAB) and fecal incontinence (FI). Key features include a quick recharge time under an hour, a battery life of 15 years, and MRI compatibility without impedance checks, aimed at improving patient quality of life.

Medtronic has announced a friendly cash tender offer to acquire Medicrea for €7.00 per share, marking a 22% premium over the last closing price. This acquisition aims to enhance Medtronic’s spine surgery capabilities by integrating Medicrea's AI-driven surgical planning and personalized implants. The transaction, supported by major Medicrea shareholders representing 44.4% of its share capital, is expected to close by the end of 2020, pending regulatory approvals. Analysts forecast the deal will be immaterial to Medtronic's adjusted earnings in the initial two years, turning accretive in fiscal year 2023.

Medtronic announced FDA clearance and CE Mark approval for its new LINQ II™ insertable cardiac monitor (ICM), enhancing remote programming capabilities for improved patient management. This device boasts a longevity of 4.5 years and heightened accuracy in detecting abnormal heart rhythms. Notably, it enables clinicians to adjust settings without in-person visits, addressing COVID-19 challenges. LINQ II offers streamlined workflows, reducing time spent on ICM transmissions by 33%, and enhances patient experience through options like smartphone integration.

Medtronic plc (MDT) has launched a significant global post-market study named DISSECT-N to assess the safety and effectiveness of the Valiant Navion™ Thoracic Stent Graft System in treating thoracic aortic dissection. The study will enroll at least 200 patients across 45 sites in North America, Europe, and Asia Pacific, with a primary focus on technical procedure success and major adverse events within one month post-procedure. This initiative responds to a critical need in treating aortic dissection, aiming to provide valuable real-world evidence and improve patient outcomes.

Medtronic reports significant three-year outcomes from the Global SYMPLICITY Registry, demonstrating that renal denervation (RDN) with the Symplicity™ System leads to substantial and lasting reductions in blood pressure (BP) for hypertensive patients. Office systolic BP decreased by 17 mmHg, with two-thirds of patients initially over 180 mmHg achieving lower BP levels. These results, achieved while patients remained on an average of four anti-hypertensive medications, underscore RDN's efficacy and safety, with a renal artery stenosis incidence of only 0.3%.

Medtronic announces FDA approval for the Percept™ PC Deep Brain Stimulation (DBS) system, incorporating BrainSense™ technology. This innovation allows for chronic capture of brain signals while delivering therapy for conditions like Parkinson's disease and OCD. The device, first implanted at Mayo Clinic, enables personalized treatment through data-driven insights. Key features include MRI compatibility, smart battery, improved longevity, and enhanced patient programming. Medtronic aims to transform care standards with this groundbreaking technology.

Medtronic announces the CE mark approval for its Evolut TAVI system to treat severe aortic stenosis in low-risk patients, now including those with bicuspid aortic valves. This new indication allows treatment for patients at extreme, high, and intermediate risks of surgical mortality. The Evolut Low Risk Trial showed TAVI's safer profile and effective outcomes, with shorter hospital stays and improved quality-of-life scores. With over 500,000 annual cases of severe aortic stenosis in Western Europe, this approval significantly increases patient access to minimally invasive valve replacement options.